[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552549":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":71,"collaborators":10,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":10,"eligibilityCriteria":80,"healthyVolunteers":77,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Population 1: Participants with intracranial neoplasms",null,"Participants with intracranial neoplasms (glial or metastatic disease) with concern for recurrence or progression on conventional imaging.",[13,14],"Drug: Fluorethyltyrosine (18-F)","Procedure: Positron Emission Tomography (PET)",{"label":16,"type":10,"description":17,"interventionNames":18},"Population 2: Participants with suspected glial neoplasms","Participants with suspected glial neoplasms (Grade 2 - 4) planning to undergo biopsy or surgery prior to non-investigational, standard-of-care, primary treatment (radiation therapy and\u002For surgery)",[13,14],[20,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Fluorethyltyrosine (18-F)","Given intravenously (IV)",[9,16],[26,27,28],"Fluoroethyltyrosine (FET)","FET","O-(2-[18F]fluoroethyl)-L-tyrosine (FET)",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"PROCEDURE","Positron Emission Tomography (PET)","Undergo Imaging Procedure",[9,16],[35,36],"PET scan","PET",[38],{"name":39,"affiliation":5,"role":40},"Javier Villanueva-Meyer, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Louise Magat","CONTACT","(415) 502-1822","Louise.Magat@ucsf.edu",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","San Francisco","California","94143","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-122.41942,37.77493,{"lat":59,"lon":58},[62,64,67,68],{"name":43,"role":44,"phone":63,"phoneExt":10,"email":46},"415-502-1822",{"name":10,"role":44,"phone":65,"phoneExt":10,"email":66},"(887) 827-3222","cancertrials@ucsf.edu",{"name":39,"role":40,"phone":10,"phoneExt":10,"email":10},{"name":69,"role":70,"phone":10,"phoneExt":10,"email":10},"Thomas Hope, MD","SUB_INVESTIGATOR",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Thomas Hope","Co-Principal Investigator, IND Holder","100552549","fluoroethyltyrosine-for-the-evaluation-of-intracranial-neoplasm-100552549",false,"NCT06474533","Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm","Inclusion Criteria:\n\n* Presence or suspicion of intracranial neoplasm in two populations:\n\n  * Population 1: Participants after primary treatment (radiation therapy and\u002For surgery) with suspicion of recurrence on MRI.\n  * Three sub-populations will be considered:\n\n    * Recurrent metastatic lesions.\n    * Recurrent high-grade gliomas (Grades 3 and 4).\n    * Recurrent low-grade gliomas (Grade 2).\n  * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.\n* Age \\> 3 years.\n\nParticipants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.\n\nExclusion Criteria:\n\n* Participants with known incompatibility to PET or Computerized tomography (CT)\u002Fmagnetic resonance imaging (MRI) scans.\n* Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.\n\n  * Sedation or anesthesia can be used for participants who cannot tolerate the exam.","ALL","4 Years",{"count":84,"type":85},199,"ESTIMATED","OBSERVATIONAL","This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.",[89],"Intracranial Neoplasm",[91],"Imaging Studies","2026-03-30",{"date":94,"type":95},"2026-04-03","ACTUAL",{"date":97,"type":95},"2024-06-21",{"date":99,"type":85},"2028-08-31",{"name":73,"class":6},1]